Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial

Liping Dou, Bo Peng, Xin Li, Lu Wang, Mingyu Jia, Lingmin Xu, Fei Li, Daihong Liu, Liping Dou, Bo Peng, Xin Li, Lu Wang, Mingyu Jia, Lingmin Xu, Fei Li, Daihong Liu

Abstract

Background: The response rate of the first-line therapy with corticosteroid for acute graft versus host disease (aGVHD) is about 50%, and steroid-refractory disease is associated with high mortality. The improved response rate to the first-line therapy of newly diagnosed aGVHD patients would result in therapeutic benefits. Ruxolitinib, a selective Janus kinase (JAK) 1/2 inhibitor, has been approved for the treatment of steroid-refractory acute GVHD. The addition of ruxolitinib to the first-line therapy may improve the efficacy of corticosteroids.

Methods: This investigator-initiated, open-label, multicenter, prospective randomized, and controlled two-arm phase II study compares the efficacy and safety of ruxolitinib combined with 1 mg/kg methylprednisolone versus 2 mg/kg methylprednisolone alone in newly diagnosed aGVHD patients. Patients with intermediate or high-risk aGVHD, as defined by the Minnesota aGVHD high-risk score and biomarker algorithm, are eligible for this study. A total of 198 patients will be randomized at a 1:1 ratio and assigned a GVHD risk (intermediate versus high risk) and disease status before transplantation (complete remission versus no complete remission). The primary endpoint is the overall response rate on day 28, which is defined as an improvement of at least one stage in the severity of aGVHD in one organ without deterioration in any other organ or disappearance of any GVHD signs from all organs without requiring new systemic immunosuppressive treatment. The secondary objectives consist of response time, response duration, overall survival, disease-free survival, non-relapse mortality, failure-free survival, and changes in serum levels of proinflammatory cytokines and GVHD-related biomarkers.

Discussion: This open-label, multicenter, two-arm randomized trial will evaluate whether the addition of ruxolitinib combined with corticosteroid is superior to corticosteroid alone in newly diagnosed high-risk aGVHD.

Trial registration: ClinicalTrials.gov NCT04061876 (version number: 2019.5.18). Registered on July 16, 2019.

Keywords: Acute graft versus host disease; Biomarker; First-line therapy; Ruxolitinib.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Flow chart illustrating the treatment schedule for enrolled patients

References

    1. Malard F, Huang XJ, Sim JPY. Treatment and unmet needs in steroid-refractory acute graft-versus-host disease. Leukemia. 2020;34(5):1229–1240. doi: 10.1038/s41375-020-0804-2.
    1. Dou L, Hou C, Ma C, Li F, Gao X, Huang W, Wang S, Gao C, Yu L, Liu D. Reduced risk of chronic GVHD by low-dose rATG in adult matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Ann Hematol. 2020;99(1):167–179. doi: 10.1007/s00277-019-03884-8.
    1. Dou LP, Li HH, Wang L, Li F, Huang WR, Yu L, Liu DH. Efficacy and safety of unmanipulated haploidentical related donor allogeneic peripheral blood stem cell transplantation in patients with relapsed/refractory acute myeloid leukemia. Chin Med J. 2018;131(7):790–798. doi: 10.4103/0366-6999.228243.
    1. Hou C, Dou L, Jia M, Li F, Wang S, Gao X, et al. Ruxolitinib Combined with Corticosteroids as First-Line Therapy for Acute Graft-versus-Host Disease in Haploidentical Peripheral Blood Stem Cell Transplantation Recipients. Transplant Cell Ther. 202;27(1):75.e1–75.e10.
    1. Zeiser R, Blazar BR. Acute graft-versus-host disease - biologic process, prevention, and therapy. N Engl J Med. 2017;377(22):2167–2179. doi: 10.1056/NEJMra1609337.
    1. Xhaard A, Launay M, Sicre de Fontbrune F, Michonneau D, Sutra Del Galy A, Coman T, Pagliuca S, Dhedin N, Robin M, Peffault de Latour R, et al. A monocentric study of steroid-refractory acute graft-versus-host disease treatment with tacrolimus and mTOR inhibitor. Bone Marrow Transplant. 2020;55(1):86–92. doi: 10.1038/s41409-019-0633-y.
    1. Escamilla Gómez V, García-Gutiérrez V, López Corral L, García Cadenas I, Pérez Martínez A, Márquez Malaver FJ, Caballero-Velázquez T, González Sierra PA, Viguria Alegría MC, Parra Salinas IM, et al. Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study. Bone Marrow Transplant. 2020;55(3):641–648. doi: 10.1038/s41409-019-0731-x.
    1. de Kort EA, van Dorp S, Blijlevens NMA, van der Velden W. Corticosteroid replacement by ruxolitinib in patients with acute GVHD experiencing severe steroid-induced side effects. Bone Marrow Transplant. 2020;55(1):253–255. doi: 10.1038/s41409-019-0526-0.
    1. Baake T, Jörß K, Suennemann J, Roßmann L, Bohnenberger H, Tuckermann JP, Reichardt HM, Fischer HJ, Reichardt SD. The glucocorticoid receptor in recipient cells keeps cytokine secretion in acute graft-versus-host disease at bay. Oncotarget. 2018;9(21):15437–15450. doi: 10.18632/oncotarget.24602.
    1. Jagasia M, Zeiser R, Arbushites M, Delaite P, Gadbaw B, Bubnoff NV. Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials. Immunotherapy. 2018;10(5):391–402. doi: 10.2217/imt-2017-0156.
    1. Zeiser R. Advances in understanding the pathogenesis of graft-versus-host disease. Br J Haematol. 2019;187(5):563–572. doi: 10.1111/bjh.16190.
    1. Li H, Kaiser TK, Borschiwer M, Bohnenberger H, Reichardt SD, Lühder F, Walter L, Dressel R, Meijsing SH, Reichardt HM. Glucocorticoid resistance of allogeneic T cells alters the gene expression profile in the inflamed small intestine of mice suffering from acute graft-versus-host disease. J Steroid Biochem Mol Biol. 2019;195:105485. doi: 10.1016/j.jsbmb.2019.105485.
    1. Schroeder MA, Choi J, Staser K, DiPersio JF. The role of Janus kinase signaling in graft-versus-host disease and graft versus leukemia. Biol Blood Marrow Transplant. 2018;24(6):1125–1134. doi: 10.1016/j.bbmt.2017.12.797.
    1. Srinagesh HK, Ferrara JLM. MAGIC biomarkers of acute graft-versus-host disease: biology and clinical application. Best Pract Res Clin Haematol. 2019;32(4):101111. doi: 10.1016/j.beha.2019.101111.
    1. Zeiser R, Socié G. The development of ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. Blood Adv. 2020;4(15):3789–3794. doi: 10.1182/bloodadvances.2020002097.
    1. Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR, Shaw BE, Flowers ME, Ruutu T, Greinix H, et al. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant. 2018;53(11):1401–1415. doi: 10.1038/s41409-018-0204-7.
    1. Srinagesh HK, Levine JE, Ferrara JLM. Biomarkers in acute graft-versus-host disease: new insights. Ther Adv Hematol. 2019;10:2040620719891358. doi: 10.1177/2040620719891358.
    1. Levine JE, Braun TM, Harris AC, Holler E, Taylor A, Miller H, Magenau J, Weisdorf DJ, Ho VT, Bolaños-Meade J, et al. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. Lancet Haematol. 2015;2(1):e21–e29. doi: 10.1016/S2352-3026(14)00035-0.
    1. Major-Monfried H, Renteria AS, Pawarode A, Reddy P, Ayuk F, Holler E, Efebera YA, Hogan WJ, Wölfl M, Qayed M, et al. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. Blood. 2018;131(25):2846–2855. doi: 10.1182/blood-2018-01-822957.
    1. Jiménez-Jorge S, Labrador-Herrera G, Rosso-Fernández CM, Rodríguez-Torres N, Pachón-Ibáñez ME, Smani Y, Márquez-Malaver FJ, Limón Ramos C, Solano C, Vázquez-López L, et al. Assessing the impact on intestinal microbiome and clinical outcomes of antibiotherapy optimisation strategies in haematopoietic stem cell transplant recipients: study protocol for the prospective multicentre OptimBioma study. BMJ Open. 2020;10(7):e034570. doi: 10.1136/bmjopen-2019-034570.
    1. Jagasia M, Perales MA, Schroeder MA, Ali H, Shah NN, Chen YB, Fazal S, Dawkins FW, Arbushites MC, Tian C, et al. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020;135(20):1739–1749. doi: 10.1182/blood.2020004823.
    1. Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, Szer J, Wagner EM, Zuckerman T, Mahuzier B, et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med. 2020;382(19):1800–1810. doi: 10.1056/NEJMoa1917635.
    1. Delgado-Martin C, Meyer LK, Huang BJ, Shimano KA, Zinter MS, Nguyen JV, Smith GA, Taunton J, Winter SS, Roderick JR, et al. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. Leukemia. 2017;31(12):2568–2576. doi: 10.1038/leu.2017.136.
    1. Yang J, Peng B, Wang L, Li X, Li F, Jin X, et al. Elevated REG3α predicts refractory aGVHD in patients who received steroids-ruxolitinib as first-line therapy. Ann Hematol. 2022;101(3):621–30.
    1. von Bubnoff N, Ihorst G, Grishina O, Röthling N, Bertz H, Duyster J, Finke J, Zeiser R. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628) BMC Cancer. 2018;18(1):1132. doi: 10.1186/s12885-018-5045-7.
    1. MacMillan ML, DeFor TE, Weisdorf DJ. The best endpoint for acute GVHD treatment trials. Blood. 2010;115(26):5412–5417. doi: 10.1182/blood-2009-12-258442.
    1. Przepiorka D, Luo L, Subramaniam S, Qiu J, Gudi R, Cunningham LC, Nie L, Leong R, Ma L, Sheth C, et al. FDA approval summary: ruxolitinib for treatment of steroid-refractory acute graft-versus-host disease. Oncologist. 2020;25(2):e328–e334. doi: 10.1634/theoncologist.2019-0627.
    1. Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, Kuick R, Misek DE, Cooke KR, Kitko CL, Weyand A, et al. A biomarker panel for acute graft-versus-host disease. Blood. 2009;113(2):273–278. doi: 10.1182/blood-2008-07-167098.
    1. Hartwell MJ, Özbek U, Holler E, Renteria AS, Major-Monfried H, Reddy P, Aziz M, Hogan WJ, Ayuk F, Efebera YA, et al. An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. JCI Insight. 2017;2(3):e89798. doi: 10.1172/jci.insight.89798.
    1. Hou C, Dou L, Jia M, Li F, Wang S, Gao X, Wang L, Jin X, Wang L, Gao C, et al. Ruxolitinib combined with corticosteroids as first-line therapy for acute graft-versus-host disease in haploidentical peripheral blood stem cell transplantation recipients. Transplant Cell Ther. 2021;27(1):75.e71–75.e10. doi: 10.1016/j.bbmt.2020.09.015.
    1. Kekre N, Antin JH. Emerging drugs for graft-versus-host disease. Expert Opin Emerg Drugs. 2016;21(2):209–218. doi: 10.1517/14728214.2016.1170117.
    1. Toubai T, Magenau J. Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease. Blood. 2020;136(4):429–440. doi: 10.1182/blood.2019000953.
    1. Coltro G, Mannelli F, Guglielmelli P, Pacilli A, Bosi A, Vannucchi AM. A life-threatening ruxolitinib discontinuation syndrome. Am J Hematol. 2017;92(8):833–838. doi: 10.1002/ajh.24775.
    1. Mohty M, Holler E, Jagasia M, Jenq R, Malard F, Martin P, Socié G, Zeiser R. Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness. Blood. 2020;136(17):1903–1906. doi: 10.1182/blood.2020007336.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit